$5.55
4.97% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Verastem, Inc. Stock price

$5.84
+0.30 5.42% 1M
+2.93 100.69% 6M
+0.67 12.96% YTD
-5.68 49.31% 1Y
-12.52 68.19% 3Y
-25.24 81.21% 5Y
-114.28 95.14% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 0.34%
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Key metrics

Market capitalization $300.68m
Enterprise Value $254.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 25.41
P/S ratio (TTM) P/S ratio 30.07
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $10.00m
EBIT (operating result TTM) EBIT $-114.96m
Free Cash Flow (TTM) Free Cash Flow $-104.80m
Cash position $88.82m
EPS (TTM) EPS $-3.49
P/E forward negative
P/S forward 11.48
EV/Sales forward 9.71
Short interest 16.40%
Show more

Is Verastem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Verastem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Verastem, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Verastem, Inc. forecast:

Buy
100%

Financial data from Verastem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10 10
-
100%
- Direct Costs 0.03 0.03
50% 50%
0%
9.97 9.97
16,717% 16,717%
100%
- Selling and Administrative Expenses 44 44
42% 42%
436%
- Research and Development Expense 81 81
33% 33%
813%
-115 -115
25% 25%
-1,149%
- Depreciation and Amortization 0.03 0.03
50% 50%
0%
EBIT (Operating Income) EBIT -115 -115
25% 25%
-1,150%
Net Profit -131 -131
50% 50%
-1,306%

In millions USD.

Don't miss a Thing! We will send you all news about Verastem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verastem, Inc. Stock News

Neutral
Business Wire
9 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical ...
Neutral
Business Wire
14 days ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress. “In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel co...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, including an oral presentation of additional analyses from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial evaluating the investigational combination of avut...
More Verastem, Inc. News

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Head office United States
CEO Dan Paterson
Employees 78
Founded 2010
Website www.verastem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today